ScripChinese firm CSPC Pharmaceutical has presented promising Phase I results for its first-in-class antibody-drug conjugate (ADC) SYS6010 in non-small cell lung cancer (NSCLC), but the contender is facing
ScripTaiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
In VivoOne of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show